Trade Names:Ganite- Injection 25 mg/mL
Exerts hypocalcemic effect by inhibiting calcium resorption from bone, possibly by stabilizing bone matrix, thereby reducing increased bone turnover.
Steady state is achieved in 24 to 48 h.
Vd is 1.27 L/kg.
Plasma Cl is 0.12 to 0.2 L/h/kg. The t ½ is 24 to 115 h. Major route of elimination is kidney.
Median is 6 to 8 days.
Treatment of symptomatic, cancer-related hypercalcemia unresponsive to adequate hydration.
Severe renal impairment (serum creatinine more than 2.5 mg/dL).
IV 100 to 200 mg/m 2 /day for 5 consecutive days.
Store unopened vials at controlled room temperature (68° to 77°F). Diluted solutions can be stored for up to 48 h at ambient room temperature (59° to 86°F) or 7 days if stored under refrigeration (36° to 46°F).
May increase risk for development of renal function impairment.
None well documented.
Tachycardia; lower extremity edema; asymptomatic hypotension.
Lethargy, confusion, dreams, hallucinations, paresthesia.
Acute optic neuritis; visual impairment; tinnitus; decreased hearing.
Nausea or vomiting; diarrhea; constipation.
Increased BUN and creatinine (13%); acute renal failure.
Mild to moderate transient hypophosphatemia (79%); decreased serum bicarbonate concentrations (50%); hypocalcemia.
Shortness of breath; rales and rhonchi; pleural effusion; pulmonary infiltrates.
Hypothermia; fever; skin rash.
Concomitant use of gallium nitrate and potentially nephrotoxic drugs (eg, aminoglycosides, amphotericin B) may increase the risk for developing severe renal function impairment in patients with cancer-related hypocalcemia. If use of potentially nephrotoxic drugs is indicated, discontinue gallium and continue hydration for several days after administration of the potentially nephrotoxic agent.
During therapy, ensure that serum calcium and phosphorous is determined before starting therapy and then daily for calcium, and twice weekly for phosphorous. If direct measurement of free-ionized calcium is not available, measure serum albumin concentration and correct serum calcium.Hypercalcemia symptoms
Frequently assess patient for signs or symptoms of hypercalcemia (eg, anorexia, lethargy, fatigue, nausea, vomiting, constipation, impaired mental status) and hypocalcemia (eg, muscle cramps, positive Chvostek or Trousseau sign, paraesthesia of lips or extremities). Be prepared to discontinue gallium infusion and administer calcium supplement if hypocalcemia develops.
Category C .
Safety and efficacy not established.
Hypercalcemia in cancer patients is commonly associated with impaired renal function. Evaluate renal function (BUN, creatinine) before starting therapy and frequently during therapy.
Ensure that patient is adequately hydrated using oral and/or IV fluids (preferably saline) and that a satisfactory urine output (eg, 2 L/day) is established before beginning therapy. Ensure that adequate hydration is maintained during therapy but avoid overhydration in patient with compromised CV function.
Acute optic neuritis and decreased hearing have occurred in some patients treated with multiple high doses of gallium combined with investigational anticancer drugs.
Nausea, vomiting, renal function impairment.
Copyright © 2009 Wolters Kluwer Health.